The Latest Breaking News from Nasdaq

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga Pro data, OptiNose (NASDAQ:OPTN) reported Q1 sales of $14.76 million. Earnings fell to a loss of $25.33 million, resulting in a 62.14% decrease from last quarter.

Benzinga Pro data, Yield10 Bioscience (NASDAQ:YTEN) reported Q1 sales of $149.00 thousand. Earnings fell to a loss of $3.33 million, resulting in a 11.78% decrease from last quarter.

Benzinga Pro data, ADMA Biologics (NASDAQ:ADMA) reported Q1 sales of $29.10 million. Earnings fell to a loss of $25.01 million, resulting in a 50.2% decrease from last quarter.

Sidus Space Inc (NASDAQ: SIDU) shares are surging Thursday on continued momentum after the company on Wednesday announced that it's part of the Collins Aerospace team, which was awarded NASA's Exploration Extravehicular Activity (xEVAS) services contr

Shares of small-cap penny stock Vivakor Inc. (NASDAQ: VIVK) are trading higher after the company announced it signed a definitive agreement to acquire Silver Fuels Delhi and White Claw Colorado City.

U.S. stocks traded lower this morning, after the Federal Reserve raised interest rates by 0.75% on Wednesday.

Tilray Brands, Inc. (NASDAQ: TLRY) (TSX:TLRY) is expanding Broken Coast’s cannabis portfolio with the launch of their summer lineup of products, including: premium craft-cannabis BC (British Columbia) flower, liquid wax vapes and butane hash o

Acorda Therapeutics Inc (NASDAQ:ACOR) announced that Esteve Pharmaceuticals GmbH launched INBRIJA 33 mg (levodopa inhalation powder, hard capsules) in Germany.  INBRIJA is indicated in the EU for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson's disease treated with a levodopa/dopa-decarboxylase inhibitor.  Under the distribution and supply agreements, Acorda…